FDA corrections and removals reg
This article was originally published in The Gray Sheet
Executive Summary
Rule slated to go into effect May 18, agency says in an April 16 Federal Register notice lifting a stay on the effective date of the reg. FDA had been awaiting approval from the Office of Management and Budget, which cleared the rule's information collection requirements through Jan. 31, 2001 ("The Gray Sheet" March 16, p. 16)
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.